Calamos Wealth Management LLC Makes New Investment in Waters Corporation $WAT

Posted by Brenda Bartman on Nov 7th, 2026

Calamos Wealth Management LLC acquired a new position in shares of Waters Corporation (NYSE:WAT – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,834 shares of the medical instruments supplier’s stock, valued at approximately $8,715,000.

Other large investors have also recently made changes to their positions in the company. Ashton Thomas Securities LLC raised its holdings in shares of Waters by 3.5% in the 3rd quarter. Ashton Thomas Securities LLC now owns 704 shares of the medical instruments supplier’s stock worth $309,000 after acquiring an additional 24 shares during the last quarter. Caitlin John LLC boosted its stake in Waters by 43.9% during the 2nd quarter. Caitlin John LLC now owns 82 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 25 shares during the last quarter. Park Avenue Securities LLC boosted its stake in Waters by 2.8% during the 3rd quarter. Park Avenue Securities LLC now owns 910 shares of the medical instruments supplier’s stock valued at $400,000 after purchasing an additional 25 shares during the last quarter. Kingswood Wealth Advisors LLC increased its holdings in Waters by 3.7% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 786 shares of the medical instruments supplier’s stock worth $345,000 after purchasing an additional 28 shares in the last quarter. Finally, Avalon Trust Co increased its holdings in Waters by 2.3% during the 1st quarter. Avalon Trust Co now owns 1,330 shares of the medical instruments supplier’s stock worth $396,000 after purchasing an additional 30 shares in the last quarter. 94.01% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Weiss Ratings raised Waters from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Barclays increased their price target on Waters from $500.00 to $530.00 and gave the company an “overweight” rating in a research report on Wednesday. Wells Fargo & Company raised their price objective on Waters from $370.00 to $400.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Wall Street Zen raised shares of Waters from a “hold” rating to a “buy” rating in a report on Monday, October 26th. Finally, Jefferies Financial Group upped their target price on shares of Waters from $450.00 to $455.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $475.48.

View Our Latest Report on WAT

Waters Price Performance

Shares of Waters stock traded up $4.84 on Friday, reaching $457.92. The stock had a trading volume of 695,768 shares, compared to its average volume of 995,254. Waters Corporation has a 1 year low of $282.77 and a 1 year high of $482.28. The company has a market cap of $44.99 billion, a P/E ratio of 196.53, a price-to-earnings-growth ratio of 2.62 and a beta of 1.16. The company has a current ratio of 1.86, a quick ratio of 1.29 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average is $434.72 and its two-hundred day moving average is $372.24.

Waters (NYSE:WAT – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The medical instruments supplier reported $4.10 EPS for the quarter, beating the consensus estimate of $4.00 by $0.10. The company had revenue of $1.77 billion during the quarter, compared to analysts’ expectations of $1.75 billion. Waters had a net margin of 3.58% and a return on equity of 11.27%. Waters’s revenue for the quarter was up 120.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.40 earnings per share. As a group, research analysts anticipate that Waters Corporation will post 14.65 EPS for the current year.

Key Waters News

Here are the key news stories impacting Waters this week:

Positive Sentiment: Waters reported $1.77 billion in third-quarter 2026 revenue and raised its full-year guidance, signaling improved expectations for the business. Waters Corporation Reports $1.77 Billion in Third Quarter 2026 Revenue and Raises Full-Year Guidance
Positive Sentiment: The company agreed to acquire MOBILion Systems, expanding its mass spectrometry and AI-powered proteomics capabilities. The strategic fit could broaden Waters’ technology offering, though the reported item does not quantify the deal’s financial impact. Waters Corporation Acquires MOBILion Systems
Positive Sentiment: JPMorgan, Barclays, KeyCorp, TD Cowen, Citigroup, and RBC issued reports indicating higher price targets or strong potential appreciation, reinforcing a favorable analyst outlook. JPMorgan price target Barclays outlook KeyCorp outlook TD Cowen price target Citigroup price target RBC outlook

About Waters

(Free Report)

Waters Corporation develops and supplies analytical instruments, software, and consumables used to identify, measure, and characterize chemical and biological materials. Its products include liquid chromatography and mass spectrometry systems, which help customers analyze complex samples.

The company serves pharmaceutical and biotechnology businesses, academic and government laboratories, and customers in fields such as food, environmental testing, and materials science. Waters operates internationally, with customers and operations across multiple regions.

Founded in 1958 by James L.